摘要
目的探究顺铂联合紫杉醇化疗在乳腺癌患者中应用效果及安全性。方法选取我院2013年5月—2015年1月收治的60例乳腺癌患者作为研究对象,所有患者均采取紫杉醇联合顺铂治疗,观察患者治疗疗效及化疗毒副反应、患者1年生存率、2年生存率。结果经治疗后,60例患者的总有效率为83.33%,患者1年生存率为83.33%,2年生存率为70.00%,化疗期间患者主要出现副反应为骨髓抑制、胃肠道反应,经有效处理后症状缓解。结论顺铂联合紫杉醇化疗在乳腺癌患者中应用效果良好,患者1年、2年生存率较高,化疗过程中存在一定毒副反应,但经处理后可缓解患者耐受,安全性较高。
Objective To explore the effect and safety of eisplatin in patients with breast cancer. Methods 60 cases of breast cancer patients in our hospital from May 2013 to January 2015 were selected as the research object. All patients were treated with paclitaxel and cisplatin. The curative effect, side effects of chemotherapy, the 1 year survival rate and the 2 year survival rate of the patients were observed. Results After treatment, the total effective rate of the 60 patients was 83.33%, the 1 year survival rate was 83.33%, and the 2 year survival rate was 70.00%. During the chemotherapy period, the main side effects were myelosuppression and gastrointestinal reaction, and the symptoms were alleviated after effective treatment. Conclusion Cisplatin and paclitaxel chemotherapy and good application effect in breast cancer patients, the 1 year and the 2 year survival rate is higher, there are certain adverse reactions during chemotherapy, but after treatment can alleviate patients with tolerance, high security.
作者
张一帆
ZHANG Yifan(Department of Tumor, Sihong Fenjinting Hospital, Suqian Jiangsu 223900, Chin)
出处
《中国继续医学教育》
2017年第17期177-179,共3页
China Continuing Medical Education
关键词
乳腺癌
顺铂
紫杉醇
疗效
毒副反应
breast cancer
cisplatin
taxol
curative effect
adverse reaction
